With CAPEX complete and no major expenses ahead, Aarti Drugs is turning its focus toward execution and efficiency. The company expects a sharp improvement in profitability as stabilized prices reveal the true strength of its business model. Mr. Patil says R&D-led process optimization, energy conservation, and the ramp-up of new facilities will together drive margin expansion. Revenue visibility stands at ₹3,200–3,500 crore within three years, with EBITDA margins seen rising to 16% or higher — signaling a confident comeback for Aarti Drugs.

See Full Page